tert-butyl N-[(1S)-1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]methyl]-2-methyl-propyl]carbamate | 1374635-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: tert-butyl N-[(1S)-1-[[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]methyl]-2-methyl-propyl]carbamate
• 英文别名: tert-butyl N-[(2S)-1-[[2-chloro-5-(3,3-diethoxyprop-1-ynyl)pyrimidin-4-yl]amino]-3-methylbutan-2-yl]carbamate
• CAS: 1374635-80-9
• 化学式: C₂₁H₃₃ClN₄O₄
• 分子量: 440.97
• InChiKey: IIMNAMUGZMLUPA-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• CDK INHIBITORS
  申请人：G1 THERAPEUTICS, INC.

  公开号：US20130237534A1

  公开（公告）日：2013-09-12

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  式I、II或III的化合物及其药用盐可用作CDK抑制剂。
• CDK Inhibitors
  申请人：G1 Therapeutics, Inc.

  公开号：US20140142299A1

  公开（公告）日：2014-05-22

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  式子I、II或III的化合物及其药学上可接受的盐，可用作CDK抑制剂。
• HSPC-sparing treatments for RB-positive abnormal cellular proliferation
  申请人：G1 Therapeutics, Inc.

  公开号：US10076523B2

  公开（公告）日：2018-09-18

  This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.

  本发明涉及用于治疗选定的 RB 阳性癌症和其它 Rb 阳性异常细胞增殖性疾病的改良化合物和方法，同时最大限度地减少与当前治疗方法相关的对健康细胞（例如健康的造血干细胞和祖细胞（HSPC））的有害影响。在一个方面，本文公开了使用本文公开的特定化合物改善对特定 RB 阳性癌症的治疗。在某些实施方案中，本文所述的化合物在给受试者用药时可作为高选择性、在某些实施方案中为短效、瞬时作用的细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂。
• Transient protection of normal cells during chemotherapy
  申请人：G1 THERAPEUTICS, INC.

  公开号：US10085992B2

  公开（公告）日：2018-10-02

  This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

  本发明涉及瞬时保护健康细胞，特别是造血干细胞和祖细胞（HSPC）以及肾脏细胞免受DNA损伤性化疗药物损害的改良化合物、组合物和方法。在一个方面，所公开的化合物可作为高选择性、短效、瞬时起作用的细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂，用于接受DNA损伤性化疗方案治疗增殖性疾病的受试者，从而改善对健康细胞的保护。
• CDK inhibitors
  申请人：G1 Therapeutics, Inc.

  公开号：US10189849B2

  公开（公告）日：2019-01-29

  Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

  式 I、II 或 III 的化合物及其药学上可接受的盐类可用作 CDK 抑制剂。